Financials
| Preliminary Results | May. 28, 2025 |
| Trading Update | Jan. 23, 2025 |
| Half-year Report | Sep. 26, 2024 |
| Posting of 2023 Annual Report & Notice of the AGM | Jun. 18, 2024 |
| Preliminary Results | Jun. 05, 2024 |
| Trading and business update | Nov. 09, 2023 |
| Interim Results for the period ended 30 June 2023 | Sep. 07, 2023 |
Proxies
| Result of 2025 Annual General Meeting | Jun. 30, 2025 |
| POSTING OF ANNUAL REPORT AND NOTICE OF AGM | Jun. 09, 2025 |
| Result of 2024 Annual General Meeting | Jul. 11, 2024 |
| Result of 2023 Annual General Meeting | Jun. 28, 2023 |
| Result of 2022 Annual General Meeting | Jun. 29, 2022 |
| Result of AGM | Jun. 30, 2021 |
| Annual General Meeting update | Jun. 18, 2021 |
Ownership Update
| Issue of LTIP Options and Share Options | Mar. 21, 2025 |
| Standard form for notification of major holdings | Jul. 18, 2024 |
| Standard form for notification of major holdings | Jul. 12, 2024 |
| Standard form for notification of major holdings | Jan. 10, 2024 |
| Standard form for notification of major holdings | Jun. 27, 2023 |
| Issue of LTIP Options and Share Options | Mar. 10, 2023 |
| Holding(s) in Company | Mar. 09, 2023 |
Announcements
| EACR 2025: Innovation in AR expression profiling | Jun. 17, 2025 |
| EACR 2025: Data demonstrating DNA dual analysis | Jun. 17, 2025 |
| Novel discoveries into the biology of cancer | Jun. 10, 2025 |
| Notice of Results | May. 23, 2025 |
| RESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME | Apr. 28, 2025 |
| Results of Eisai Phase 2 pilot study | Mar. 21, 2025 |
| Novel findings using Parsortix | Feb. 06, 2025 |